167 related articles for article (PubMed ID: 32770465)
1. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs.
Nakagawa M; Nawa N; Takeichi E; Shimizu T; Tsuchiya J; Sato A; Miyoshi M; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Fujiwara T; Watanabe M; Tanaka Y; Asahina Y;
J Gastroenterol; 2020 Oct; 55(10):990-999. PubMed ID: 32770465
[TBL] [Abstract][Full Text] [Related]
2. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients.
Kikukawa K; Uchida-Kobayashi S; Tamori A; Yoshida K; Kotani K; Motoyama H; Kozuka R; Hagihara A; Fujii H; Morikawa H; Enomoto M; Murakami Y; Kawada N
Ann Hepatol; 2020; 19(4):367-372. PubMed ID: 32444247
[TBL] [Abstract][Full Text] [Related]
3. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
4. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C.
Takemura K; Takizawa E; Tamori A; Nakamae M; Kubota H; Uchida-Kobayashi S; Enomoto M; Kawada N; Hino M
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630450
[TBL] [Abstract][Full Text] [Related]
5. Mac-2-Binding Protein Glycosylation Isomer as a Novel Predictor of Hepatocellular Carcinoma Recurrence in Patients with Hepatitis C Virus Eradication.
Yugawa K; Maeda T; Nagata S; Sakai A; Edagawa M; Omine T; Kometani T; Yamaguchi S; Konishi K; Hashimoto K
Ann Surg Oncol; 2022 Apr; 29(4):2711-2719. PubMed ID: 34729653
[TBL] [Abstract][Full Text] [Related]
6. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
[TBL] [Abstract][Full Text] [Related]
7. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Nagata H; Nakagawa M; Nishimura-Sakurai Y; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Goto F; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Tojo N; Tohda S; Asahina Y; Watanabe M;
Hepatol Int; 2016 Nov; 10(6):956-964. PubMed ID: 27435935
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.
Tamaki N; Kurosaki M; Loomba R; Izumi N
Ann Lab Med; 2021 Jan; 41(1):16-24. PubMed ID: 32829576
[TBL] [Abstract][Full Text] [Related]
9. Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response.
Harimoto N; Itoh S; Yamanaka T; Hagiwara K; Ishii N; Tsukagoshi M; Watanabe A; Araki K; Yoshizumi T; Shirabe K
Anticancer Res; 2022 Jan; 42(1):245-251. PubMed ID: 34969731
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
11. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
[TBL] [Abstract][Full Text] [Related]
12. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.
Mak LY; Ko M; To E; Wong DK; Ma JH; Hui TL; Seto WK; Fung J; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2019 Oct; 34(10):1817-1823. PubMed ID: 30786068
[TBL] [Abstract][Full Text] [Related]
13. Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C.
Kawata K; Atsukawa M; Ohta K; Chida T; Noritake H; Arai T; Iwakiri K; Yasuda S; Toyoda H; Okubo T; Hiraoka A; Watanabe T; Uojima H; Nozaki A; Tani J; Morishita A; Kageyama F; Sasada Y; Nagasawa M; Matsushita M; Oyaizu T; Mikami S; Ikegami T; Abe H; Matsuura K; Tanaka Y; Tsubota A
Hepatol Commun; 2022 Aug; 6(8):1855-1869. PubMed ID: 35344290
[TBL] [Abstract][Full Text] [Related]
14. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
[TBL] [Abstract][Full Text] [Related]
15. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
[TBL] [Abstract][Full Text] [Related]
16. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
17. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
18. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B.
Hsu YC; Jun T; Huang YT; Yeh ML; Lee CL; Ogawa S; Cho SH; Lin JT; Yu ML; Nguyen MH; Tanaka Y
Aliment Pharmacol Ther; 2018 Nov; 48(10):1128-1137. PubMed ID: 30306612
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
